Further to the Transformation Announcement made on 20 June 2018, the Board of Queensland Bauxite Limited (ASX:QBL) has recognised that due to current market conditions, the intended capital raise at 8c is no longer an immediate practical option. As a result, the Board has decided to amend the raising price for the recompliance.
Nanollose Limited (ASX:NC6) is pleased to provide its Appendix 4C cash flow statement for the quarter ending 30th June 2018, together with the following operational update whereby all goals set out in the Company's previous quarterly report have been achieved.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of its cancer vaccine which met the primary endpoint of safety and tolerability. The study known as the ACTIVATE trial, is the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2018.
Oventus Medical Ltd (ASX:OVN) announces its Appendix 4C Report for the three-month period ending 30 June 2018 (Q4 FY2018) and is pleased to provide a review of progress made during the quarter.
Nanollose Ltd (ASX:NC6) provides the Company Update Presentation.
Queensland Bauxite Limited (ASX:QBL) is delighted to announce that Medcan Australia, has now been issued with both an Import & Export Licence under the ODC.
